Literature DB >> 35147708

[Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners].

Sabrina Voesch1, M Bitzer2, N Malek2.   

Abstract

The update of the S3 German guideline for the management of the hepatocellular carcinoma and biliary tract cancer contains a comprehensive revision of the guideline for hepatocellular carcinoma and establishes a new guideline for biliary tract cancer. In recent years several studies have been conducted to improve diagnostic and therapeutic options for liver cancer. Magnetic resonance imaging (MRI) and biopsy are important for the diagnosis of hepatocellular carcinoma or cholangiocarcinoma. This guideline shows the progress in the treatment options for hepatocellular carcinoma, including advances in liver transplantation, bridging and downstaging. For cholangiocarcinoma there is a focus on interventional treatment and resection. This guideline also emphasizes the need of molecular diagnostics and the resulting treatment options in targeted therapy.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Biliary tract cancer; Biopsy; Liver neoplasms; Magnetic resonance imaging; Molecular diagnostics

Mesh:

Year:  2022        PMID: 35147708     DOI: 10.1007/s00117-022-00970-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  73 in total

1.  The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients.

Authors:  Angelo Sangiovanni; Gian Maria Prati; Pierangelo Fasani; Guido Ronchi; Raffaella Romeo; Matteo Manini; Ersilio Del Ninno; Alberto Morabito; Massimo Colombo
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

2.  Coffee drinking and hepatocellular carcinoma risk: a meta-analysis.

Authors:  Francesca Bravi; Cristina Bosetti; Alessandra Tavani; Vincenzo Bagnardi; Silvano Gallus; Eva Negri; Silvia Franceschi; Carlo La Vecchia
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

3.  Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.

Authors:  Man-Fung Yuen; Yasuhito Tanaka; Daniel Yee-Tak Fong; James Fung; Danny Ka-Ho Wong; John Chi-Hang Yuen; David Yiu-Kuen But; Annie On-On Chan; Benjamin Chun-Yu Wong; Masashi Mizokami; Ching-Lung Lai
Journal:  J Hepatol       Date:  2008-09-21       Impact factor: 25.083

4.  Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.

Authors:  Hansen Dang; Yee Hui Yeo; Satoshi Yasuda; Chung-Feng Huang; Etsuko Iio; Charles Landis; Dae Won Jun; Masaru Enomoto; Eiichi Ogawa; Pei-Chien Tsai; An Le; Matthew Liu; Mayumi Maeda; Brian Nguyen; Nathan Ramrakhiani; Linda Henry; Ramsey Cheung; Akihiro Tamori; Takashi Kumada; Yasuhito Tanaka; Ming-Lung Yu; Hidenori Toyoda; Mindie H Nguyen
Journal:  Hepatology       Date:  2020-05-08       Impact factor: 17.425

5.  Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan.

Authors:  Manami Inoue; Itsuro Yoshimi; Tomotaka Sobue; Shoichiro Tsugane
Journal:  J Natl Cancer Inst       Date:  2005-02-16       Impact factor: 13.506

6.  Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.

Authors:  Giuseppe Cabibbo; Ciro Celsa; Vincenza Calvaruso; Salvatore Petta; Irene Cacciola; Maria Rita Cannavò; Salvatore Madonia; Margherita Rossi; Bianca Magro; Francesca Rini; Marco Distefano; Licia Larocca; Tullio Prestileo; Giuseppe Malizia; Gaetano Bertino; Francesco Benanti; Anna Licata; Ignazio Scalisi; Giovanni Mazzola; Maria Antonietta Di Rosolini; Giuseppe Alaimo; Alfonso Averna; Fabio Cartabellotta; Nicola Alessi; Salvatore Guastella; Maurizio Russello; Gaetano Scifo; Giovanni Squadrito; Giovanni Raimondo; Franco Trevisani; Antonio Craxì; Vito Di Marco; Calogero Cammà
Journal:  J Hepatol       Date:  2019-04-06       Impact factor: 25.083

7.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

8.  Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort.

Authors:  Veronica Wendy Setiawan; Lynne R Wilkens; Shelly C Lu; Brenda Y Hernandez; Loïc Le Marchand; Brian E Henderson
Journal:  Gastroenterology       Date:  2014-10-08       Impact factor: 22.682

9.  The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition.

Authors:  Krasimira Aleksandrova; Christina Bamia; Dagmar Drogan; Pagona Lagiou; Antonia Trichopoulou; Mazda Jenab; Veronika Fedirko; Isabelle Romieu; H Bas Bueno-de-Mesquita; Tobias Pischon; Kostas Tsilidis; Kim Overvad; Anne Tjønneland; Marie-Christine Bouton-Ruault; Laure Dossus; Antoine Racine; Rudolf Kaaks; Tilman Kühn; Christos Tsironis; Eleni-Maria Papatesta; George Saitakis; Domenico Palli; Salvatore Panico; Sara Grioni; Rosario Tumino; Paolo Vineis; Petra H Peeters; Elisabete Weiderpass; Marko Lukic; Tonje Braaten; J Ramón Quirós; Leila Luján-Barroso; María-José Sánchez; Maria-Dolores Chilarque; Eva Ardanas; Miren Dorronsoro; Lena Maria Nilsson; Malin Sund; Peter Wallström; Bodil Ohlsson; Kathryn E Bradbury; Kay-Tee Khaw; Nick Wareham; Magdalena Stepien; Talita Duarte-Salles; Nada Assi; Neil Murphy; Marc J Gunter; Elio Riboli; Heiner Boeing; Dimitrios Trichopoulos
Journal:  Am J Clin Nutr       Date:  2015-11-11       Impact factor: 7.045

10.  Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes.

Authors:  Jason C Simeone; Jay P Bae; Byron J Hoogwerf; Qian Li; Axel Haupt; Ayad K Ali; Marilyn K Boardman; Beth L Nordstrom
Journal:  Clin Epidemiol       Date:  2017-12-14       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.